DE2945788A1 - Arzneimittel und seine verwendung - Google Patents
Arzneimittel und seine verwendungInfo
- Publication number
- DE2945788A1 DE2945788A1 DE19792945788 DE2945788A DE2945788A1 DE 2945788 A1 DE2945788 A1 DE 2945788A1 DE 19792945788 DE19792945788 DE 19792945788 DE 2945788 A DE2945788 A DE 2945788A DE 2945788 A1 DE2945788 A1 DE 2945788A1
- Authority
- DE
- Germany
- Prior art keywords
- adjuvant
- compound
- antigen
- immune substance
- blood cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000002671 adjuvant Substances 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 239000002960 lipid emulsion Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 229960005486 vaccine Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 231100000614 poison Toxicity 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000008344 egg yolk phospholipid Substances 0.000 claims description 4
- LYFYWXLKKQIOKO-UHFFFAOYSA-N 3,3-diaminopentan-1-ol Chemical compound CCC(N)(N)CCO LYFYWXLKKQIOKO-UHFFFAOYSA-N 0.000 claims description 3
- 239000000428 dust Substances 0.000 claims description 3
- 229940068998 egg yolk phospholipid Drugs 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000007096 poisonous effect Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000003998 snake venom Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 32
- 108091007433 antigens Proteins 0.000 description 32
- 102000036639 antigens Human genes 0.000 description 32
- 241001494479 Pecora Species 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 210000000601 blood cell Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 229940028435 intralipid Drugs 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 230000035931 haemagglutination Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 229940125810 compound 20 Drugs 0.000 description 7
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 6
- 241000700198 Cavia Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- -1 pollen Substances 0.000 description 4
- 238000010517 secondary reaction Methods 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000000568 immunological adjuvant Substances 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000012646 vaccine adjuvant Substances 0.000 description 3
- 229940124931 vaccine adjuvant Drugs 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 229940124873 Influenza virus vaccine Drugs 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005804 Eastern equine encephalitis Diseases 0.000 description 1
- 208000031912 Endemic Flea-Borne Typhus Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010014979 Epidemic typhus Diseases 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 206010028282 Murine typhus Diseases 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 208000008939 Pneumonic Pasteurellosis Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000577483 Salmonella enterica subsp. enterica serovar Paratyphi B Species 0.000 description 1
- 240000003705 Senecio vulgaris Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005806 Western equine encephalitis Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960004784 allergens Drugs 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000005901 endemic typhus Diseases 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000033687 granuloma formation Effects 0.000 description 1
- 229940046528 grass pollen Drugs 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000000468 intravenous fat emulsion Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241000189072 typhus group Species 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/088,638 US4310550A (en) | 1979-10-26 | 1979-10-26 | Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2945788A1 true DE2945788A1 (de) | 1981-05-07 |
| DE2945788C2 DE2945788C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-01-28 |
Family
ID=22212534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19792945788 Granted DE2945788A1 (de) | 1979-10-26 | 1979-11-13 | Arzneimittel und seine verwendung |
Country Status (7)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0058021A3 (en) * | 1981-02-06 | 1982-10-27 | Beecham Group Plc | Pharmaceutical compositions |
| IL74289A (en) * | 1985-02-10 | 1989-02-28 | Israel State | Vaccine system comprising a live-non-virulent vaccine and an adjuvant |
| NL9000207A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1990-01-29 | 1991-08-16 | Duphar Int Res | |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| EP2295075A1 (en) | 2001-01-04 | 2011-03-16 | University Of Saskatchewan | Enterohemorragic escherichia coli vaccine |
| ZA200604412B (en) | 2003-10-31 | 2007-09-26 | Univ British Columbia | Bacterial virulence factors and uses thereof |
| KR20070008625A (ko) * | 2004-04-05 | 2007-01-17 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
| US20080102067A1 (en) * | 2006-10-25 | 2008-05-01 | Cook Mark E | Immunogenic composition |
| WO2017011919A1 (en) | 2015-07-22 | 2017-01-26 | University Of Saskatchewan | Mycoplasma vaccines and uses thereof |
| BR112022021258A2 (pt) | 2020-04-20 | 2023-01-17 | Univ Saskatchewan | Composições e métodos para prevenir, controlar e diagnosticar infecções micobacterianas |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3872171A (en) * | 1971-05-24 | 1975-03-18 | Pfizer | Polyamines as antiviral agents in animals |
| US4034040A (en) * | 1971-05-24 | 1977-07-05 | Pfizer Inc. | Xylene-diamines as antiviral agents |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA725596A (en) * | 1960-08-26 | 1966-01-11 | J. Wretlind Arvid | Method of preparing intravenously injectable fat emulsions free from side reactions or complications |
| US4173641A (en) * | 1978-05-15 | 1979-11-06 | Pfizer Inc. | Di-O-n-alkyl glycerol derivatives as immune stimulants |
-
1979
- 1979-10-26 US US06/088,638 patent/US4310550A/en not_active Expired - Lifetime
- 1979-11-13 JP JP14789679A patent/JPS5671024A/ja active Granted
- 1979-11-13 DE DE19792945788 patent/DE2945788A1/de active Granted
-
1980
- 1980-05-13 PT PT71236A patent/PT71236A/pt unknown
- 1980-10-23 CA CA000363110A patent/CA1163562A/en not_active Expired
- 1980-10-23 NZ NZ195354A patent/NZ195354A/xx unknown
- 1980-10-24 AU AU63664/80A patent/AU522338B2/en not_active Expired
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3872171A (en) * | 1971-05-24 | 1975-03-18 | Pfizer | Polyamines as antiviral agents in animals |
| US4034040A (en) * | 1971-05-24 | 1977-07-05 | Pfizer Inc. | Xylene-diamines as antiviral agents |
Also Published As
| Publication number | Publication date |
|---|---|
| PT71236A (en) | 1980-06-01 |
| AU522338B2 (en) | 1982-05-27 |
| NZ195354A (en) | 1982-12-21 |
| AU6366480A (en) | 1981-04-30 |
| US4310550A (en) | 1982-01-12 |
| JPS6225646B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1987-06-04 |
| JPS5671024A (en) | 1981-06-13 |
| DE2945788C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-01-28 |
| CA1163562A (en) | 1984-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69304521T2 (de) | Impfstoff Adjuvans | |
| DE69937343T2 (de) | Adjuvanszusammensetzung und methoden zu deren verwendung | |
| DE69434956T2 (de) | Auf einer Emusion und MPL basierte Adjuvantien für Impfstoffe | |
| DE69724970T2 (de) | Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a | |
| DE60110822T2 (de) | Zubereitung zur immunisierung gegen den aids-virus | |
| DE69826842T2 (de) | Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a | |
| DE69605296T3 (de) | Impfstoffe die ein saponin und ein sterol enthalten | |
| DE3712767C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE68927679T2 (de) | Immunhilfsmittel aus Liposome enthaltend Lymphokin IL -2 | |
| DE69934179T2 (de) | Zusammensetzung enthaltend ein Antigen, ein TH-1 induzierendes Adjuvans und eine im Wasser schwer lösliche Aminosäure zur Verwendung in der Immunisierung | |
| EP1144001A2 (de) | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation | |
| DE3911442A1 (de) | Impfstoff-praeparation | |
| WO2000015251A2 (de) | Influenzavirus-impfstoffzusammensetzung | |
| DE2606118A1 (de) | Gamma-globuline fuer intravenoese injektion und verfahren zur herstellung von solchem gamma-globulin | |
| DE69623072T2 (de) | Impfstoffzusammensetzung für Säugetiere enthaltend Squalen oder Squalan, Phospholipid und ein Tensid als Adjuvans | |
| DE69115514T2 (de) | Liposomenhaltige intranasale Impfstofformulierung | |
| DE69127694T2 (de) | Herstellung und verwendung von transfer-faktor | |
| DE68922109T2 (de) | Gamma-inulin-zusammensetzungen. | |
| EP0363835B1 (de) | Verwendung von Zink- oder Eisenhydroxid zur Adjuvierung von Antigenlösungen und auf diese Weise adjuvierte Antigenlösungen | |
| DE2603321A1 (de) | Emulsion auf der grundlage eines stoffwechselfaehigen pflanzlichen oels und wasser | |
| DE2945788A1 (de) | Arzneimittel und seine verwendung | |
| DE19511276C2 (de) | Adjuvans auf der Basis kolloidaler Eisenverbindungen | |
| DE69813070T2 (de) | Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex | |
| DE1924304C3 (de) | Diäthylaminoäthyldextran (DEAE-D) als Adjuvans für Impfstoffe zur aktiven Immunisierung von Säugetieren | |
| EP0445710B1 (de) | Verwendung von Zink-Calciumhydroxid, Lecithin und PAO zur Adjuvierung von Antigenlösungen und auf diese Weise adjuvierte Antigenlösungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8128 | New person/name/address of the agent |
Representative=s name: LEDERER, F., DIPL.-CHEM. DR., PAT.-ANW., 8000 MUEN |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |